论文部分内容阅读
肠道易激综合征(IBS)病因复杂,无特异而持久有效的治疗方法。本文研究一种新型抗毒蕈碱化合物(?)溴化西咪托品治疗IBS 患者的作用。病人与方法:1986年1月～1986年6月门诊患者中有68例被诊断为IBS,其中48例符合研究标准作随机双盲对照研究,患者年龄18～65岁。研究包括三周筛选期和6个月治疗期,在筛选期采集病史、体检和实验室检查包括血清电解质和大便常规,并确定其基线数据,在治疗期间由患者记录大便次数、腹痛频率及疼痛强度,每月随访1次,筛选期和治疗末期分别发给Middlesex 医院调查表(MHQ),并作认识行为评价(C
Intestinal irritable bowel syndrome (IBS) complex causes, no specific and lasting effective treatment. This article studies the role of a novel anti-muscarinic compound (?) Cimetidine bromide in patients with IBS. Patients and Methods: Sixty-eight outpatients between January 1986 and June 1986 were diagnosed with IBS. Forty-eight patients were eligible for study as a randomized, double-blind, controlled study of patients aged 18-65 years. The study included a three-week screening period and a six-month treatment period. Medical records were collected during the screening period. Physical examinations and laboratory tests included serum electrolytes and stool routine and baseline data. Patient records of stool frequency, frequency and pain of abdominal pain during treatment Intensity, monthly follow-up, screening and treatment were sent to the Middlesex Hospital Questionnaire (MHQ), and cognitive behavior assessment (C